

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

STA Foslevodopa-foscarbidopa for treating Parkinson’s disease with motor symptoms

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

The patient organisation Parkinson’s UK raised equality considerations within their consultation comments. The comments suggested consideration should be given to:

- Older people who may not be deemed suitable for deep-brain stimulation or levodopa-carbidopa intestinal gel, or for whom these treatments are not accessible (for example, those not close to a specialist centre)
- Those people who have apomorphine contraindicated because they either exhibit psychosis or orthostatic hypotension
- People with Parkinson’s disease who may face difficulties in accessing and using the technology (for example, due to a need for refrigeration and during the initial phase of getting used to using the administration pump)
- People with visual impairments who may have difficulties with using the administration pump.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

The initial view is that consideration of people who do not live close to a

specialist centre or who may face difficulties of using the pump due to the need for refrigeration will not be considered as equalities issues. This is because issues related to these considerations cannot be addressed in a technology appraisal. Geographic location is not a protected characteristic.

Where appropriate, the committee will consider whether its recommendations could have a different impact on people protected by the equality legislation than on the wider population, including on people contraindicated to existing treatments due to age and people with visual impairments.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

The equality considerations raised by the patient organisation were discussed during the scoping workshop. All participants (including the patient organisation) agreed that there were no required changes to the scope based on this.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

No.

Approved by Associate Director (name): Ross Dent

Date: 01/04/2022